Zivo Bioscience adopts new Director Equity Plan, boosts share reserves, grants equity to directors and officers

Zivo Bioscience, Inc.

Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.
Amended 2021 Plan reserve from 166,666 to 1,000,000 shares; terminated 2019 Plan.
Granted 127,364 restricted shares to directors replacing cancelled options; additional 261,619 shares for unpaid 2023 fees.
Issued 1,031,425 stock options to officers: CEO John Payne (217,431), CFO Keith Marchiando (444,498) replacing prior options and cash bonus.
Total unregistered securities issued: 426,671 common shares and options for 1,031,425 shares; outstanding shares at 3,278,807.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.